Joel Hay is a professor of Pharmaceutical and Health Economics at the USC School of Pharmacy, with joint appointments in the USC Schaeffer Center and the Department of Economics in the USC Dornsife College of Letters, Arts and Sciences. He was the founding chair of the former Department of Pharmaceutical Economics and Policy at the School of Pharmacy.
He also serves as the USC project coordinator for the Rand Evidence-Based Medicine Practice Centers of Southern California, funded by the U.S. Agency for Health Research and Quality, and co-investigator at the USC Alzheimer Research Center, funded by the California Department of Health Services. He is a health economics research scholar at the UCLA Center for Vaccine Research. He is a founding executive board member of the American Society for Health Economics and of the International Society for Pharmaceutical Economics and Outcomes Research.
Hay was founding editor-in-chief of Value in Health, the peer-reviewed scientific journal of the International Society for Pharmacoeconomics and Outcomes Research, until 2003. This journal, started in 1998, became Medline-listed in 2002.Value in Health was ranked #1 in two categories for 2004 by the ISI Journal Citation Reports® (JCR) with an impact factor of 3.657. Value in Health led all other journals listed both in the Health Care Sciences and Services category in the JCR Science edition and in the Health Policy & Services category in the JCR Social Sciences edition.
He has authored more than 600 peer-reviewed scientific articles, abstracts, editorials and reports in the fields of pharmaceutical economics, health economics, outcomes research, disease management, statistics, econometrics, epidemiology and healthcare.
Areas of Expertise (10)
Sociological Costs of Drug and Alcohol Abuse
Health Insurance Reform
Health Care Markets
Yale University: Ph.D., Economics 1980
Yale University: M.Phil, Economics 1976
Yale University: M.A., Economics 1975
Amherst College: B.A., Economics 1974
- Academy of Managed Care Pharmacy
- American Association of Colleges of Pharmacy
- American Economic Association
- American Public Health Association
- American Society of Health Economists
Selected Media Appearances (4)
COVID-19 By Country
Joel Hay led the development of a COVID-19 econometric model with country-specific logistic growth curves as functions of time from Day Zero (when the cumulative number of reported cases surpasses 100).
Has Sweden Found the Right Solution to the Coronavirus?
National Review online
By Joel W. Hay, PhD and John Fund
Unlike other countries, it has so far avoided both isolation and economic ruin.
Public Policy Panic About the COVID-19 Pandemic Not Supported by the Facts
The Washington Times online
By Joel W. Hay, PhD and Cynthia L. Gong, PharmD, PhD
Social isolation measures only for those at highest risk and aggressive contact tracing are more effective and less expensive than sending everyone home and shutting down the economy, Hay and Gong write.
A Cost-Effectiveness Analysis of Pre-Exposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex with Men
USC Schaeffer Center online
By Joel W. Hay, PhD and Neeraj Sood, PhD
In the ongoing fight against HIV and AIDS, PrEP and test-and-treat offer cost-effective alternatives to the status quo, with success depending on medication adherence and initiation rates.
Selected Articles (5)
Joel W. Hay
Peer-reviewed journals could make a key contribution to improving scientific rigor and real-world healthcare decision-maker acceptability by requiring that VHDM models, source code, and data used in published articles be made freely available to interested readers.
Afsaneh Barzi, Sang K. Cho, Joel W. Hay, Heinz-Josef Lenz, Fang-Shu Ou, Axel Grothey, Tanios S. Bekaii-Saab
Based on the outcomes demonstrated in the ReDOS study, the dose optimization strategy of regorafenib results in favorable cost-effectiveness under a typical US willingness-to-pay threshold of $150,000 per QALY.
Afsaneh Barzi, Xiayu Jiao, Joel W. Hay, Sarmad Sadeghi
Adjuvant chemotherapy (AC) for stage II colon cancer remains a controversial topic. We used Surveillance Epidemiology End Results (SEER) linkage with Medicare claims to explore the benefits of AC and cost of care in pts with CC-II diagnosed between 2004-2010.
Gong CL, Dasgupta-Tsinikas S, Zangwill KM, Bolaris M, Hay JW
This study determines the potential net monetary benefit of an early onset sepsis calculator-based approach for management of neonates exposed to maternal intrapartum fever, compared to existing guidelines.
Cynthia L. Gong, Kenneth M. Zangwill, Joel W. Hay, Daniella Meeker, Jason N. Doctor
This study determines the cost-effectiveness of three behavioral economic interventions designed to reduce inappropriate antibiotic prescriptions for ARIs.